QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs ALT 803 (Primary)
- Indications Cancer; HIV infections
- Focus Pharmacokinetics
- Acronyms QUILT-1.004
- Sponsors Altor BioScience Corporation
- 06 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 28 Feb 2018.
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.
- 29 Dec 2017 New trial record